A prospective pilot study on DACHAO intervention for improving embryo quality metrics in IVF/ICSI failure cases

Area of Science:

• Reproductive Biology
• Assisted Reproductive Technology (ART)

Background:

• Embryo quality is critical for successful assisted reproductive technology (ART) outcomes.
• Poor embryo morphology is linked to increased risks of implantation failure and pregnancy loss.
• Limited therapeutic options exist to enhance embryo development, highlighting the need for novel interventions.

Purpose of the Study:

• To evaluate the efficacy of DACHAO Reco18, a natural extract formulation, in improving reproductive outcomes for in vitro fertilization (IVF) patients with a history of poor embryo quality.
• To assess the impact of DACHAO Reco18 on key embryological parameters and pregnancy rates.

Main Methods:

• A prospective self-controlled study involving 68 IVF patients (aged 20-40) with documented poor embryo quality and previous IVF/ICSI failure.
• Participants underwent a six-week oral treatment with DACHAO Reco18.
• Outcomes were compared between pre- and post-intervention cycles, focusing on embryo parameters, oocyte yield, fertilization, implantation, and pregnancy rates.

Main Results:

• DACHAO Reco18 significantly improved oocyte yield (7.955 to 8.955), fertilization (3.731 to 5.463), and Day-3 viable embryos (1.896 to 3.000).
• High-quality embryo rates increased by 118.52% (0.567 to 1.239), with overall quality improving from 30.729% to 44.107%.
• Statistically significant improvements were observed in implantation rate (0% to 32.00%), biochemical pregnancy (0% to 24.00%), and clinical pregnancy (0% to 21.05%).
• Subgroup analysis showed a reduction in FSH levels in hyper-gonadotropic patients (12.083 to 9.941 mIU/mL).

Conclusions:

• A six-week DACHAO Reco18 intervention shows promise in improving ovarian response and embryological outcomes in IVF patients with poor embryo quality.
• The formulation may also reduce FSH levels in hyper-gonadotropic individuals.
• Further verification through randomized controlled trials is warranted to establish DACHAO Reco18 as an adjuvant ART treatment.